Know more

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

  • Cookies strictly necessary for the proper functioning of the site
  • Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally. You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore, you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Name of the cookie


Shelf life

CAS and PHP session cookies

Login credentials, session security



Saving your cookie consent choices

12 months

Audience measurement cookies (AT Internet)

Name of the cookie


Shelf life


Trace the visitor's route in order to establish visit statistics.

13 months


Store the anonymous ID of the visitor who starts the first time he visits the site

13 months


Identify the numbers (unique identifiers of a site) seen by the visitor and store the visitor's identifiers.

13 months

About the AT Internet audience measurement tool :

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

  • The data collected are not cross-checked with other processing operations
  • The deposited cookie is only used to produce anonymous statistics
  • The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

  • to offer interactive content;
  • improve usability and facilitate the sharing of content on social networks;
  • view videos and animated presentations directly on our website;
  • protect form entries from robots;
  • monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at or by post at :


24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

Menu Logo Principal Ministère de l'agriculture et de l'alimentation Ministère de l'enseignement supérieur, de la recherche et de l'innovation Logo_ANR Centre national de la recherche scientifique Fondation pour la recherche sur la biodiversité Laboratoire LABOGENA : analyses génétiques pour les espèces animales Logo_VetAgro Sup ANTAGENE

Home page

New scientific results for targeted therapies for mucosal melanoma

Photo de Vlad Chețan provenant de Pexels
In humans, mucosal melanoma (MM) is a rare and aggressive cancer. The canine model is frequently and spontaneously affected by MM, facilitating sample collection and study of its genetic basis. Through integrative genomic and transcriptomic analysis of 32 canine MM samples, we identified two molecular subgroups of MM with different microenvironment and structural variant (SV) content.

We demonstrated that VS is associated with recurrently amplified regions and identified novel candidate oncogenes (TRPM7, GABPB1 and SPPL2A) for MM. Our results suggest the existence of two molecular subgroups of MM that may benefit from dedicated therapies, such as immune checkpoint inhibitors or targeted therapies, in both human and veterinary medicine. Mucosal melanoma (MM) is a rare and aggressive clinical cancer. Despite recent advances in genetics and treatment, the prognosis of MM remains poor. Canine MM provides a relevant spontaneous and immunocompetent model to decipher the genetic basis and explore treatments for MM. We performed an integrative genomic and transcriptomic analysis of 32 canine MM samples, which identified two molecular subgroups with different microenvironment and structural variant (SV) content. Overexpression of genes related to the microenvironment and T-cell response was associated with tumors with lower SV content, whereas overexpression of pigmentation-related pathways and oncogenes, such as TERT, was associated with high SV load. Using whole genome sequencing, we showed that focal amplifications characterized complex chromosomal rearrangements targeting oncogenes, such as MDM2 or CDK4, and a recurrently amplified region on canine chromosome 30. We also demonstrated that the genes TRPM7, GABPB1, and SPPL2A, located in this CFA30 region, play a role in cell proliferation, and thus can be considered as novel candidate oncogenes for human MM. Our results suggest the existence of two molecular subgroups of MM that could benefit from specific therapies, such as immune checkpoint inhibitors or targeted therapies, in both human and veterinary medicine.


  • Anaïs Prouteau

See also

Prouteau, A.; Mottier, S.; Primot, A.; Cadieu, E.; Bachelot, L.; Botherel, N.; Cabillic, F.; Houel, A.; Cornevin, L.; Kergal, C.; Corre, S.; Abadie, J.; Hitte, C.; Gilot, D.; Lindblad-Toh, K.; André, C.; Derrien, T.; Hedan, B. Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets. Cancers 2022, 14, 276.